Tango Therapeutics, Inc.
TNGXTango Therapeutics, Inc. (TNGX) is a biotechnology company focused on developing targeted cancer therapies. The company leverages genetic and genomic research to identify vulnerabilities in cancer cells, aiming to create precision medicines that selectively attack tumors while minimizing effects on normal tissue. Founded with a focus on innovative and personalized cancer treatments, Tango Therapeutics is engaged in the discovery and development of novel therapeutic candidates.
Company News
Tango Therapeutics announced the appointment of Sung Lee, Executive Vice President and CFO at Cytokinetics, to its Board of Directors. Lee brings over 20 years of finance leadership experience from roles at major biopharmaceutical companies including Vir Biotechnology, MorphoSys, Sangamo Therapeutics, and Gilead Sciences. His appointment is inten...
Tango Therapeutics' CEO Barbara Weber will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference, presenting a live webcast about the company's precision medicine cancer research.
Tango Therapeutics reported a steep decline in Q2 2025 revenue and wider net losses, with ongoing clinical trials in targeted oncology therapies and the early termination of its Gilead partnership.
Tango Therapeutics initiated a Phase 1/2 clinical trial combining TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib to treat RAS-mutant MTAP-deleted pancreatic and lung cancers, targeting potential new precision cancer therapies.
Tango Therapeutics, a clinical-stage biotechnology company, announced the dosing of the first patient in a Phase 1/2 trial for its drug candidate TNG456 in patients with MTAP-deleted glioblastomas and other solid tumors.
